Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B
(1998) In Haemophilia 4(1). p.56-59- Abstract
- Two patients with haemophilia B and high-responding inhibitor to factor IX were subjected to immune tolerance induction according to the Malmo protocol, including high dosage of factor IX, cyclophosphamide and intravenous gammaglobulin. In one of the patients the treatment was preceded by extracorporeal protein A adsorption. Both patients had previously been subjected to immune tolerance induction without success and as an attempt to improve the tolerance induction regimen and lower cost, factor IX was given as continuous infusion, with a dose of around 300 units per kg body weight daily for 3 weeks. The inhibitor level declined in one of the patients but tolerance was not achieved. In the second patient the inhibitor level remained high.... (More)
- Two patients with haemophilia B and high-responding inhibitor to factor IX were subjected to immune tolerance induction according to the Malmo protocol, including high dosage of factor IX, cyclophosphamide and intravenous gammaglobulin. In one of the patients the treatment was preceded by extracorporeal protein A adsorption. Both patients had previously been subjected to immune tolerance induction without success and as an attempt to improve the tolerance induction regimen and lower cost, factor IX was given as continuous infusion, with a dose of around 300 units per kg body weight daily for 3 weeks. The inhibitor level declined in one of the patients but tolerance was not achieved. In the second patient the inhibitor level remained high. Despite the failure of the treatment in these two cases, we propose that the constant antigen load provided by the continuous infusion of modern, safe, purified factor IX concentrate may theoretically be of greater benefit in immune tolerance induction than the varying load resulting from intermittent infusions. Larger study materials are needed to show if this is so. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1113243
- author
- Tengborn, Lilian LU and Berntorp, Erik LU
- organization
- publishing date
- 1998
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- continuous infusion, factor IX inhibitor, Haemophilia B, immune tolerance induction, protein A adsorption
- in
- Haemophilia
- volume
- 4
- issue
- 1
- pages
- 56 - 59
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:9873867
- scopus:0031598555
- ISSN
- 1351-8216
- DOI
- 10.1046/j.1365-2516.1998.00142.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Coagulation Research Unit (013242510), Emergency medicine/Medicine/Surgery (013240200)
- id
- 571f7c01-68e2-4eed-bb11-73fbb2f38f8a (old id 1113243)
- date added to LUP
- 2016-04-01 12:08:36
- date last changed
- 2022-01-26 23:25:15
@article{571f7c01-68e2-4eed-bb11-73fbb2f38f8a,
abstract = {{Two patients with haemophilia B and high-responding inhibitor to factor IX were subjected to immune tolerance induction according to the Malmo protocol, including high dosage of factor IX, cyclophosphamide and intravenous gammaglobulin. In one of the patients the treatment was preceded by extracorporeal protein A adsorption. Both patients had previously been subjected to immune tolerance induction without success and as an attempt to improve the tolerance induction regimen and lower cost, factor IX was given as continuous infusion, with a dose of around 300 units per kg body weight daily for 3 weeks. The inhibitor level declined in one of the patients but tolerance was not achieved. In the second patient the inhibitor level remained high. Despite the failure of the treatment in these two cases, we propose that the constant antigen load provided by the continuous infusion of modern, safe, purified factor IX concentrate may theoretically be of greater benefit in immune tolerance induction than the varying load resulting from intermittent infusions. Larger study materials are needed to show if this is so.}},
author = {{Tengborn, Lilian and Berntorp, Erik}},
issn = {{1351-8216}},
keywords = {{continuous infusion; factor IX inhibitor; Haemophilia B; immune tolerance induction; protein A adsorption}},
language = {{eng}},
number = {{1}},
pages = {{56--59}},
publisher = {{Wiley-Blackwell}},
series = {{Haemophilia}},
title = {{Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B}},
url = {{http://dx.doi.org/10.1046/j.1365-2516.1998.00142.x}},
doi = {{10.1046/j.1365-2516.1998.00142.x}},
volume = {{4}},
year = {{1998}},
}